Drug intelligence / Profile preview

AT9311

Development stage: Preclinical
Lead developer: Astex Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

AT9311 (also known as NVP-LCQ195) is an orally active small molecule inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CDK1, CDK2, CDK3, CDK5, and CDK9. Discovered by Astex using its proprietary fragment-based drug discovery platform, Pyramid, the drug is being developed in collaboration with Novartis. By inhibiting these kinases, AT9311 disrupts the cell cycle and transcription, offering potential therapeutic benefit in the treatment of various cancers (neoplasms), immune system disorders, and cardiovascular diseases.

Targets

CDK6 (Cyclin-dependent kinase 6)CDK7CDK2 (Cyclin-dependent kinase 2)P-TEFb (Positive transcription elongation factor b)CDK5 (Cyclin-dependent kinase 5)CDK3 (Cyclin-dependent kinase 3)CDK1 (Cyclin-dependent kinase 1)

Beyond the preview

Go deeper on AT9311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT9311.

Explore the full profile